ULK1 and non-small cell lung carcinoma: It is reported that co-treatment with Cur and crizotinib upregulates the expression of miR-142-5p to target Ulk1 and inhibit autophagy in NSCLC cells, lowering the resistance of lung carcinoma to crizotinib [92].